Pfizer, Phase II clinical study of MultiStem expected in early 2014
Phase II ulcerative colitis trial being conducted by Pfizer, if positive will greatly influence future partnerships and collaborations with Athersys.
"Pfizer has worked closely with Athersys to design and execute the MultiStem clinical study over the last three years," commented Dr. Ruth McKernan, Chief Scientific Officer at Neusentis, a Pfizer Research Unit. "We believe this to be a rigorous, statistically-robust clinical trial, which will provide important insight into MultiStem's potential for patients with ulcerative colitis. Due to some challenges with recruitment associated with the volume of clinical studies in this area, we now look forward to results in early 2014."
"We are encouraged by the progress in developing MultiStem, our lead platform and proprietary allogeneic stem cell product"
Sentiment on ATHX is moving in the right direction. In fact, the stock currently has a Zacks Rank #2 (Buy)